Our clinical world will be governed by information technology and mathematical predictions, whether an entire community, a hospital, or a single patient is involved. Genetics and genomics, analyzed by robust internet-based programs that will reside in a cyber-cloud, will become an integral part of our world and will govern our clinical decisions. Medical devices combined with imaging will continue to evolve and offer new therapeutic options. Combinations of a device and a drug eluted over the right time and in the right space through microchip mechanisms

will be developed. Robotic and remote catheterization technologies will continue to evolve and introduce Inhibitors,research,lifescience,medical precision into the manually operated world.31–33 Surgery will be completely transformed to become minimally invasive and robotically driven, eliminating the need for large incisions. Genetically oriented molecular

and cellular therapies Inhibitors,research,lifescience,medical will eventually beat cancer. As we reach the limit of our society to pay for medical care, cost sensitivity will remain a major factor Inhibitors,research,lifescience,medical in the development and wide availability of new devices and new therapeutics. Abbreviations: FDA Food and Drug Administration; IPC induced pluripotent cells; PCI percutaneous coronary intervention; PTCA percutaneous transluminal coronary angioplasty; TAVR transarterial aortic valve replacement. Footnotes Conflict of interest: Dr Beyar is also Chairman of the Board of the Rambam Research Fund Inhibitors,research,lifescience,medical and is on the Board of BioRap of the Rappaport Family Research Institute on

Medical Research. He is also co-founder of Instent and Corindus (previously Navicath), a Technion-Rambam incubator company.
In vivo studies were conducted in order to evaluate whether the active antioxidant components of PJ are absorbed. Recent studies examined the bioavailability and signaling pathway metabolism of punicalagin in the rat as an animal model.5,6 Two groups of rats were studied. Inhibitors,research,lifescience,medical One group was fed for 37 days with standard rat diet (n = 5), and the second one with the same diet plus 6% punicalagin (n = 5). The daily intake of punicalagin ranged from 0.6 g to 1.2 g. Glucuronides of methyl ether derivatives of ellagic acid and punicalagin were detected in plasma. 6H-Dibenzo [b, d] pyran-6-one derivatives were PD184352 (CI-1040) also observed in the plasma, especially during the last few weeks of the study. In urine, the metabolite urolithin was observed along with 6H-dibenzo [b, d] pyran-6-one derivatives, and they were present as aglycones or as glucuronides. It was concluded that since only 3%–6% of the ingested punicalagin was detected as such, or as metabolites in urine and feces, the majority of this ellagitannin has to be converted to undetectable metabolites or accumulated in non-analyzed tissues. Only traces of punicalagin metabolites were detected in liver or kidney.